A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT00241007
First received: October 14, 2005
Last updated: November 7, 2011
Last verified: October 2005
  Purpose

SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301


Condition Intervention Phase
Hypertension
Drug: VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Adverse events and serious adverse events at each study visit for 54 weeks

Secondary Outcome Measures:
  • Change from baseline in diastolic blood pressure from baseline after 54 weeks
  • Change from baseline in systolic blood pressure from baseline after 54 weeks
  • Change from baseline in standing diastolic and systolic blood pressure after 54 weeks
  • Hematology and blood chemistries up to 54 weeks
  • Physical condition including pregnancy, pulse and weight at each study visit

Enrollment: 836
Study Start Date: December 2003
Study Completion Date: March 2005
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

SUCCESSFUL COMPLETION OF STUDY CVAH631C2301

-

Exclusion Criteria:

  • NONE
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00241007

Locations
United States, New Jersey
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
Sponsors and Collaborators
Novartis
Investigators
Study Chair: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis
ClinicalTrials.gov Identifier: NCT00241007     History of Changes
Other Study ID Numbers: CVAH631C2301E1
Study First Received: October 14, 2005
Last Updated: November 7, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
HYPERTENSION, VALSARTAN

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Valsartan
Hydrochlorothiazide
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators

ClinicalTrials.gov processed this record on October 19, 2014